Neuromodulation Market - [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] - Forecasts to 2017
NEW YORK, Jan. 17, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p01083659/Neuromodulation-Market-–-[Spinal-Cord-Stimulation-SCS-Vagus-Nerve-Stimulation-VNS-Gastric-Electrical-Stimulation-GES-Deep-Brain-Stimulation-DBS-Sacral-Nerve-Stimulation-SNS--Transcranial-Magnetic-Stimulation-TMS]-–-Forecasts-to-2017 .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory
Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non–invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS).
The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder.
The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. The large pool of patients that suffer from depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor offers the neuromodulation industry opportunities to grow in the next five years. The market for treatment of tinnitus, in particular, represents an emerging application of neuromodulation. According to the American Tinnitus Association, about 50 million people currently (2012) suffer from this disease in the U.S.
This report estimates the market for six major segments, namely, spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, gastric electrical stimulation, transcranial magnetic stimulation, and others. The report also estimates the market for different neuromodulation techniques as well as geographic analysis of each segment in North America, Europe, Asia-Pacific, and Rest of the World. As technologies develop and the number of trained physician increases, the likelihood of neuromodulation being seen as life-changing treatment will increase dramatically. It is estimated that the market for neuromodulation will be shared largely by deep brain stimulation and spinal cord stimulation.
The key players in the neuromodulation devices market are Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical (U.S.), Enteromedics, Inc (U.S.), Neuropace, Inc (U.S.), Zynex, Inc (U.S.) and Neuronetics, Inc (U.S.). The emerging players in this market are Functional Neuromodulation, Ltd (U.S.), Microtransponder (U.S.), and Neurosigma, Inc (U.S.).
Scope of the Report
The research report categorizes the global neuromodulation devices market by procedure, technology, and application. These markets are broken down into segments and sub-segments, providing exhaustive value-volume analysis for 2010, 2011, and 2012 as well as forecast up to 2017. Each market is also analyzed by geography (North America, Europe, Asia-Pacific, and Rest of the World to provide in-depth information on the global scenario.
Global Neurostimulation Devices Market, by Procedure:
Internal Neurostimulation
Spinal Cord Stimulation (SCS)
Failed Back Surgery Syndrome
Chronic Pain
Ischemic Pain
Others
Deep Brain Stimulation (DBS)
Movement Disorders
Parkinson's Disease
Alzheimer's Disease
Dystonia
Tourette's Syndrome
Others
Chronic Pain
Depression
Post-Traumatic Coma
Sacral Nerve Stimulation (SNS)
Urine Incontinence
Fecal Incontinence
Vagus Nerve Stimulation (VNS)
Epilepsy disease
Heart Failure
Tinnitus
Others
Gastric Electrical Stimulation (GES)
Gastroparesis
Others
External Neurostimulation
Transcranial Magnetic Stimulation (TMS)
Depression
Tinnitus
Migraine
Stroke
Others
Transcutaneous Electrical Nerve Stimulation (TENS)
Global Neurostimulation Devices Market, by Geography
North AmericaEuropeAsia-PacificRest of the World
TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 KEY TAKE-AWAYS 16
1.2 REPORT DESCRIPTION 16
1.3 MARKETS COVERED 18
1.4 RESEARCH METHODOLOGY 20
1.4.1 MARKET SIZE 20
1.4.2 MARKET SHARE 20
1.4.3 KEY DATA POINTS FROM SECONDARY SOURCES 20
1.4.4 KEY DATA POINTS FROM PRIMARY SOURCES 21
1.4.5 ASSUMPTIONS 21
1.5 STAKEHOLDERS 21
2 EXECUTIVE SUMMARY 22
3 MARKET OVERVIEW 25
3.1 INTRODUCTION 26
3.2 MARKET SEGMENTATION 27
3.3 MARKET DYNAMICS 29
3.3.1 DRIVERS 29
3.3.1.1 Increasing incidence of neurological disorders to spur market growth 29
3.3.1.2 Unprecedented global aging to fuel market growth 29
3.3.1.3 Strong product pipeline to propel the market 30
3.3.1.4 Expanded target applications and new indications are expected to stimulate growth of neuromodulation devices 30
3.3.1.5 Investments and funds – an impetus for market growth 31
3.4 RESTRAINTS 32
3.4.1.1 An unfavourable reimbursement scenario hinders market growth 32
3.4.1.2 Lack of trained professionals likely to hamper market growth 33
3.5 MARKET SHARE ANALYSIS 33
4 GLOBAL NEUROMODULATION MARKET (INTERNAL & EXTERNAL) 35
4.1 INTRODUCTION 36
4.2 INTERNAL STIMULATION 37
4.2.1 SPINAL CORD STIMULATION (SCS) MARKET 37
4.2.1.1 Major applications 39
4.2.1.1.1 Failed back surgery syndrome 40
4.2.1.1.2 Chronic pain 40
4.2.1.1.3 Ischemia 42
4.2.2 DEEP BRAIN STIMULATION (DBS) 42
4.2.2.1 Major applications 45
4.2.2.1.1 Parkinson's disease 46
4.2.2.1.2 Dystonia 47
4.2.2.1.3 Tremor 47
4.2.2.1.4 Alzheimer's 48
4.2.3 SACRAL NERVE STIMULATION (SNS) 48
4.2.3.1 Major applications 51
4.2.3.1.1 Urine incontinence 52
4.2.3.1.2 Fecal incontinence 53
4.2.4 VAGUS NERVE STIMULATION (VNS) 53
4.2.4.1 Major applications 56
4.2.4.1.1 Epilepsy 57
4.2.4.1.2 Others 58
4.2.5 GASTRIC ELECTRICAL STIMULATION (GES) 58
4.3 EXTERNAL STIMULATION 61
4.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) 61
4.3.2 TRANSCRANIAL MAGNETIC STIMULATION (TMS) 64
5 GEOGRAPHIC ANALYSIS 685.1 INTRODUCTION 695.2 NORTH AMERICA 725.3 EUROPE 805.4 ASIA 875.5 REST OF THE WORLD 976 COMPETITIVE LANDSCAPE 1066.1 INTRODUCTION 1066.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, CONTRACTS & JOINT VENTURES 1086.3 NEW PRODUCT LAUNCH 1106.4 EXPANSION 1126.5 OTHER DEVELOPMENTS 1136.6 APPROVALS 1147 COMPANY PROFILES 122(Overview, Financials, Products & Services, Strategy, & Developments)*7.1 ANM ADAPTIVE NEUROMODULATION GMBH 1227.2 BIOCONTROL MEDICAL, LTD. 1257.3 BOSTON SCIENTIFIC CORPORATION 1287.4 CERBOMED GMBH 1367.5 CYBERONICS, INC. 1397.6 ENDOSTIM, INC. 1447.7 ENTEROMEDICS, INC. 1477.8 THE MAGSTIM COMPANY LIMITED 1507.9 MEDTRONIC, INC. 1537.10 NEURONETICS, INC. 1597.11 NEUROPACE, INC. 1627.12 NEUROSIGMA, INC. 1647.13 NEVRO CORPORATION 1677.14 RS MEDICAL 1697.15 SPINAL MODULATION, INC. 1727.16 ST. JUDE MEDICAL 1747.17 SYNAPSE BIOMEDICAL, INC. 1827.18 UROPLASTY, INC. 1847.19 ZYNEX, INC. 188*Details on financials, product & services, strategy, and developments might not be captured in case of unlisted companies.
LIST OF TABLES
TABLE 1 GLOBAL NEUROMODULATION MARKET, BY PROCEDURE,2010 – 2017 ($MILLION) 23TABLE 2 GLOBAL NEUROMODULATION MARKET, BY MODALITY,2010 – 2017 ($MILLION) 23TABLE 3 SPINAL CORD STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 38TABLE 4 SPINAL CORD STIMULATION MARKET VOLUME, BY GEOGRAPHY,2010 – 2017 (NO OF UNITS) 39TABLE 5 GLOBAL SPINAL CORD STIMULATION MARKET, BY APPLICATION,2010 – 2017 ($MILLION) 41TABLE 6 DEEP BRAIN STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 44TABLE 7 DEEP BRAIN STIMULATION MARKET VOLUME, BY GEOGRAPHY,2010-2017 (NO OF UNITS) 45TABLE 8 GLOBAL DEEP BRAIN STIMULATION MARKET, BY APPLICATION,2010 – 2017 ($MILLION) 46TABLE 9 SACRAL NERVE STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 50TABLE 10 SACRAL NERVE STIMULATION MARKET VOLUME, BY GEOGRAPHY,2010 – 2017 (NO OF UNITS) 51TABLE 11 GLOBAL SACRAL NERVE STIMULATION MARKET, BY APPLICATION,2010 – 2017 ($MILLION) 52TABLE 12 VAGUS NERVE STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 55TABLE 13 VAGUS NERVE STIMULATION MARKET VOLUME, BY GEOGRAPHY,2010 – 2017 (NO OF UNITS) 56TABLE 14 GLOBAL VAGUS NERVE STIMULATION MARKET, BY APPLICATION,2010 – 2017 ($MILLION) 57TABLE 15 GASTRIC ELECTRICAL STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 59TABLE 16 GASTRIC ELECTRICAL STIMULATION MARKET VOLUME,BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS) 60TABLE 17 GLOBAL GASTRIC ELECTRICAL STIMULATION MARKET,BY APPLICATION, 2010-2017 ($MILLION) 61TABLE 18 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET,BY GEOGRAPHY, 2010 – 2017($MILLION) 63TABLE 19 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET VOLUME, BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS) 64TABLE 20 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 65TABLE 21 TRANSCRANIAL MAGNETIC STIMULATION MARKET VOLUME,BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS) 66TABLE 22 GLOBAL TRANSCRANIAL MAGNETIC STIMULATION MARKET,BY APPLICATION, 2010 – 2017 ($MILLION) 67TABLE 23 NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 69TABLE 24 EXTERNAL NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 70TABLE 25 INTERNAL NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 71TABLE 26 GLOBAL EXTERNAL NEUROMODULATION MARKET, BY MODALITY,2010 – 2017 ($MILLION) 71TABLE 27 GLOBAL EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO OF UNITS) 72TABLE 28 NORTH AMERICA: NEUROMODULATION DEVICES MARKET,BY PROCEDURE, 2010 – 2017 ($MILLION) 73TABLE 29 NORTH AMERICA: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 74TABLE 30 NORTH AMERICA: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 75TABLE 31 NORTH AMERICA: EXTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 75TABLE 32 NORTH AMERICA: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 76TABLE 33 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 76TABLE 34 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 77TABLE 35 NORTH AMERICA: SACRAL NERVE STIMULATION, BY COUNTRY,2010 – 2017 ($MILLION) 77TABLE 36 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 78TABLE 37 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 78TABLE 38 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 79TABLE 39 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 79TABLE 40 EUROPE: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,2010 – 2017 ($MILLION) 81TABLE 41 EUROPE: INTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION) 81TABLE 42 EUROPE: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 82TABLE 43 EUROPE: EXTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION) 83TABLE 44 EUROPE: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 83TABLE 45 EUROPE: SPINAL CORD STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 84TABLE 46 EUROPE: DEEP BRAIN STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 84TABLE 47 EUROPE: SACRAL NERVE STIMULATION, BY REGION,2010 – 2017 ($MILLION) 85TABLE 48 EUROPE: VAGUS NERVE STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 85TABLE 49 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 86TABLE 50 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET,BY REGION, 2010 – 2017 ($MILLION) 86TABLE 51 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 87TABLE 52 ASIA: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,2010 – 2017 ($MILLION) 88TABLE 53 ASIA: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 89TABLE 54 ASIA: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS) 90TABLE 55 ASIA: EXTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION) 90TABLE 56 ASIA: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS) 91TABLE 57 ASIA: SPINAL CORD STIMULATION MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 92TABLE 58 ASIA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 93TABLE 59 ASIA: SACRAL NERVE STIMULATION, BY COUNTRY,2010 – 2017 ($MILLION) 94TABLE 60 ASIA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 95TABLE 61 ASIA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 96TABLE 62 ROW: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,2010 – 2017 ($MILLION) 97TABLE 63 ROW: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 98TABLE 64 ROW: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS) 99TABLE 65 ROW: EXTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION) 99TABLE 66 ROW: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS) 100TABLE 67 ROW: SPINAL CORD STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 100TABLE 68 ROW: DEEP BRAIN STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 101TABLE 69 ROW: SACRAL NERVE STIMULATION, BY REGION,2010 – 2017 ($MILLION) 102TABLE 70 ROW: VAGUS NERVE STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 102TABLE 71 ROW: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 103TABLE 72 ROW: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 104TABLE 73 ROW: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 104TABLE 74 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, CONTRACTS & JOINT VENTURES, 2010 – 2012 108TABLE 75 NEW PRODUCT LAUNCH, 2010 – 2012 110TABLE 76 EXPANSION, 2010 – 2012 112TABLE 77 OTHER DEVELOPMENTS, 2010 – 2012 113TABLE 78 APPROVALS, 2010 – 2012 114TABLE 79 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION) 129TABLE 80 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION) 129TABLE 81 BOSTON SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 130TABLE 82 CYBERONICS, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION) 140TABLE 83 CYBERONICS, INC.: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 140TABLE 84 MEDTRONIC, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION) 154TABLE 85 MEDTRONIC, INC: TOTAL REVENUE, BY SEGMENTS,2009 – 2011 ($MILLION) 154TABLE 86 MEDTRONIC, INC.: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 155TABLE 87 ST. JUDE MEDICAL, INC: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION) 175TABLE 88 ST. JUDE MEDICAL, INC: TOTAL REVENUE, BY SEGMENTS,2009 – 2011 ($MILLION) 175TABLE 89 ST. JUDE MEDICAL, INC: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 176TABLE 90 UROPLASTY, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2010-2012 ($MILLION) 185TABLE 91 UROPLASTY, INC.: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 ($MILLION) 185TABLE 92 ZYNEX, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION) 189TABLE 93 ZYNEX, INC.: TOTAL REVENUE, BY SEGMENTS,2009 – 2011 ($MILLION) 189
LIST OF FIGURES
FIGURE 1 NEUROMODULATION MARKET SEGMENTATION 28FIGURE 2 MARKET DYNAMICS 32FIGURE 3 NEUROMODULATION MARKET SHARE ANALYSIS, BY REVENUE, 2011 34FIGURE 4 KEY GROWTH STRATEGIES, 2010 – 2012 107
__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article